Targeting Aurora Kinases with Danusertib (PHA-739358) Inhibits Growth of Liver Metastases from Gastroenteropancreatic Neuroendocrine Tumors in an Orthotopic Xenograft Model

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinical Cancer Research

• Publication date

  2012-07-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-11-2968PMID 22753592
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gastroenteropancreatic Neuroendocrine Tumours

  2019cited by this paper
• Danusertib, an aurora kinase inhibitor

  2012cited by this paper
• Everolimus for Advanced Pancreatic Neuroendocrine Tumors

  2012cited by this paper
• Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

  2011cited by this paper
• Everolimus for advanced pancreatic neuroendocrine tumors.

  2011cited by this paper
• Aurora B: a new prognostic marker and therapeutic target in cancer.

  2011cited by this paper
• Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors

  2011cited by this paper
• RGB marking facilitates multicolor clonal cell tracking

  2011cited by this paper
• Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.

  2011cited by this paper
• Targeted radiotherapy with radiolabeled somatostatin analogs.

  2011cited by this paper
• Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib

  2010cited by this paper
• Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.

  2010cited by this paper
• Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.

  2010cited by this paper
• Shared and separate functions of polo-like kinases and aurora kinases in cancer

  2010cited by this paper
• ZM447439, a Novel Promising Aurora Kinase Inhibitor, Provokes Antiproliferative and Proapoptotic Effects Alone and in Combination with Bio- and Chemotherapeutic Agents in Gastroenteropancreatic Neuroendocrine Tumor Cell Lines

  2009influential reference
• Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.

  2009cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.

  2009cited by this paper
• Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

  2008cited by this paper
• Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth

  2008cited by this paper
• P38 MAP Kinase Signaling Is Required for the Conversion of CD4+CD25− T Cells into iTreg

  2008cited by this paper
• Loss of Nuclear p27 Expression and Its Prognostic Role in Relation to Cyclin E and p53 Mutation in Gastroenteropancreatic Neuroendocrine Tumors

  2008influential reference
• Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors.

  2008cited by this paper
• Gastroenteropancreatic neuroendocrine tumours.

  2008cited by this paper
• PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

  2007cited by this paper
• An Orthotopic Model of Pancreatic Somatostatin Receptor (SSTR)-Positive Tumors Allows Bimodal Imaging Studies Using 3T MRI and Animal PET-Based Molecular Imaging of SSTR Expression

  2007cited by this paper
• The role of the organ microenvironment in the biology and therapy of cancer metastasis

  2007cited by this paper
• Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.

  2007cited by this paper
• PHA-739358, an Aurora Kinase Inhibitor, Induces Clinical Responses in Chronic Myeloid Leukemia Harboring T315I Mutations of BCR-ABL.

  2007cited by this paper
• Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells

  2006cited by this paper
• Identification of transplanted human cells in animal tissues.

  2006cited by this paper
• Hepatocyte transplantation activates hepatic stellate cells with beneficial modulation of cell engraftment in the rat

  2005cited by this paper
• Hepatic targeting of transplanted liver sinusoidal endothelial cells in intact mice

  2005cited by this paper
• Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)

  2005cited by this paper
• Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours

  2005cited by this paper
• Overexpression of Aurora-A Contributes to Malignant Development of Human Esophageal Squamous Cell Carcinoma

  2004cited by this paper
• Aurora-kinase inhibitors as anticancer agents

  2004cited by this paper
• Ablative Therapies for Liver Metastases of Gastroenteropancreatic Endocrine Tumors

  2004cited by this paper
• Overexpression and Amplification of Aurora-A in Hepatocellular Carcinoma

  2004cited by this paper
• Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer.

  2003cited by this paper
• Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes.

  2003cited by this paper
• Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1.

  2003cited by this paper
• Radiofrequency Tissue Ablation Using Cooled Tip for Liver Metastases of Endocrine Tumors

  2002cited by this paper
• Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells.

  2000cited by this paper
• Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.

  1998cited by this paper
• What is the Optimal Rodent Model for Anti-tumor Drug Testing?

  1998cited by this paper

• AURKC Promotes Clear Cell Renal Cell Carcinoma Proliferation Through Upregulation of ERp57

  2025cites this paper
• A comprehensive review on role of Aurora kinase inhibitors (AKIs) in cancer therapeutics.

  2024cites this paper
• Drosophila Screening Identifies Dual Inhibition of MEK and AURKB as an Effective Therapy for Pancreatic Ductal Adenocarcinoma.

  2023cites this paper
• Recent progress of experimental model in pancreatic neuroendocrine tumors: drawbacks and challenges

  2023cites this paper
• Repurposing Study of 4-Acyl-1-phenylaminocarbonyl-2-substituted-piperazine Derivatives as Potential Anticancer Agents—In Vitro Evaluation against Breast Cancer Cells

  2023cites this paper
• Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets

  2021influential citation
• Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy

  2021cites this paper
• Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer

  2021cites this paper
• Insights into the biology and treatment strategies of pancreatic neuroendocrine tumors.

  2019cites this paper
• Mouse models in endocrine tumors.

  2019cites this paper
• A Ploidy Increase Promotes Sensitivity of Glioma Stem Cells to Aurora Kinases Inhibition

  2019cites this paper
• Function and clinical relevance of RHAMM isoforms in pancreatic tumor progression

  2019cites this paper
• Dynamics of human protein kinases linked to drug selectivity

  2018cites this paper
• Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model

  2018cites this paper
• Dynamics of human protein kinase Aurora A linked to drug selectivity

  2018cites this paper
• Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms

  2018cites this paper
• An Aurora kinase inhibitor, AMG900, inhibits glioblastoma cell proliferation by disrupting mitotic progression

  2018cites this paper
• The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability.

  2018cites this paper
• Multi-color RGB marking enables clonality assessment of liver tumors in a murine xenograft model

  2017cites this paper
• Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets

  2017cites this paper
• Dictating genomic destiny: Epigenetic regulation of pancreatic neuroendocrine tumours.

  2017cites this paper
• Osteotropism of neuroendocrine tumors: role of the CXCL12/CXCR4 pathway in promoting EMT in vitro

  2017cites this paper
• Aurora Kinase A and Gastrointestinal Malignancies

  2016cites this paper
• RSUME is implicated in tumorigenesis and metastasis of pancreatic neuroendocrine tumors

  2016cites this paper
• Multi-kinase inhibitors, AURKs and cancer

  2016cites this paper
• Aurora‐A Kinase: A Potent Oncogene and Target for Cancer Therapy

  2016cites this paper
• Aurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A Review

  2015cites this paper
• Design, synthesis, and biofunctional evaluation of novel pentacyclic triterpenes bearing O-[4-(1-piperazinyl)-4-oxo-butyryl moiety as antiproliferative agents.

  2015cites this paper
• FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors

  2015cites this paper
• Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 – 2013)

  2014cites this paper
• Electrochemical and spectrophotometric characterisation of protein kinase inhibitor and anticancer drug danusertib

  2013cites this paper
• Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?

  2013cites this paper
• Phase I Studies

  year unknowncites this paper